ARTICLE | Company News
ImaRx, Microbix deal
January 28, 2008 8:00 AM UTC
The companies signed a letter of intent for Microbix to develop ImaRx's Abbokinase urokinase for certain indications, such as clearing catheters of blood clots, for which the thrombolytic is in preclinical development. Other licensed indications include cancer and ophthalmology. ImaRx is eligible for royalties. ...